Book contents
- Club Drugs and Novel Psychoactive Substances
- Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction
- Chapter 1 Introduction
- Chapter 2 What Are Club Drugs and NPS and Why Are They Important?
- Chapter 3 A Brief History of NPS Production and Distribution
- Chapter 4 Classification Framework for Club Drugs and NPS
- Chapter 5 The Clinical Challenge of Club Drugs and NPS
- Part II Stimulant Drugs
- Part III Depressant Drugs
- Part IV Synthetic Cannabinoid Receptor Agonists
- Part V Hallucinogens
- References
- Index
Chapter 5 - The Clinical Challenge of Club Drugs and NPS
from Part I - Introduction
Published online by Cambridge University Press: 21 September 2020
- Club Drugs and Novel Psychoactive Substances
- Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction
- Chapter 1 Introduction
- Chapter 2 What Are Club Drugs and NPS and Why Are They Important?
- Chapter 3 A Brief History of NPS Production and Distribution
- Chapter 4 Classification Framework for Club Drugs and NPS
- Chapter 5 The Clinical Challenge of Club Drugs and NPS
- Part II Stimulant Drugs
- Part III Depressant Drugs
- Part IV Synthetic Cannabinoid Receptor Agonists
- Part V Hallucinogens
- References
- Index
Summary
The clinical assessment framework for club drugs and NPS is largely the same as for all psychoactive drugs. This book focuses on adverse health effects, but it is important to remember that although outside the scope of this book, assessment of adverse effects should include consideration of social morbidities such as loss of employment and stable housing.
- Type
- Chapter
- Information
- Club Drugs and Novel Psychoactive SubstancesThe Clinician's Handbook, pp. 13 - 22Publisher: Cambridge University PressPrint publication year: 2020